Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase I Study of LB-100 With Docetaxel in Solid Tumors

This study has been completed.
Information provided by (Responsible Party):
Lixte Biotechnology Holdings, Inc. Identifier:
First received: April 18, 2013
Last updated: January 23, 2017
Last verified: September 2016
The purpose of this study is to test the safety of an investigational drug called LB-100 for Injection for treatment of solid tumors, when given with or without docetaxel. LB-100 is a small molecule that in laboratory and animal studies has shown activity when used by itself or together with drugs approved to treat some types of cancer (chemotherapeutic agents). Docetaxel is a drug that has been approved for the treatment of some types of cancer; one of the trade names for docetaxel is Taxotere®. The study is in 2 parts. Part 1: Patients will receive injections of LB-100. Part 2: Patients will receive injections of LB-100 and docetaxel. This is the first study where LB-100 for Injection will be used in humans.

Condition Intervention Phase
Drug: LB-100 for Injection
Drug: Docetaxel
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors

Resource links provided by NLM:

Further study details as provided by Lixte Biotechnology Holdings, Inc.:

Primary Outcome Measures:
  • Number of patients with adverse events as a measure of safety and tolerability of LB-100 for Injection treatment plus docetaxel. [ Time Frame: Starting from date of first dose up to 30 days after last dose. ]

Enrollment: 29
Study Start Date: February 2013
Study Completion Date: September 2016
Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LB-100 for Injection and Docetaxel
Part 1: LB-100 infusion. Part 2: LB-100 infusion and docetaxel infusion.
Drug: LB-100 for Injection
Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
Drug: Docetaxel
Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
Other Name: Taxotere


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Part 1 only: Patients with histologically or cytologically proven progressive or metastatic solid tumors who have failed standard treatment and have no other effective treatment available.

    Part 2 only: Patients with histologically or cytologically proven progressive or metastatic solid tumors who have failed standard treatment and have no other effective treatment available, or docetaxel-naive patients who have failed standard treatment and have tumors for which a docetaxel-based regimen would be appropriate.

  2. Part 2 only: Patients must be docetaxel-naive.
  3. Patients must have a life expectancy of at least 12 weeks.
  4. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  5. Patients must be men and women >= 18 years of age.
  6. Patients must have recovered from all acute adverse effects (excluding alopecia) of prior therapies to baseline or <= grade 1 prior to study entry.
  7. Patients must have adequate bone marrow function, defined as an absolute neutrophil count >= 1.5 x 10^9/L and a platelet count >= 100 x 10^9/L.
  8. Patients must have adequate renal function, defined as serum creatinine <= 1.5 x upper limit of normal (ULN) for the institution or a calculated creatinine clearance [Cockcroft-Gault method] must be >= 60 mL/min/1.73 m^2).
  9. Patients must have adequate hepatic function, defined as:

    • Part 1 only: plasma total bilirubin <= 1.5 mg/dL, alanine transaminase (ALT) and aspartate transaminase (AST) <= 2.5 X ULN.
    • Part 2 only: plasma total bilirubin <= ULN; ALT and/or AST <= 1.5 X ULN concomitant with alkaline phosphatase <= 2.5 X ULN.
  10. Female patients of childbearing potential must have a negative serum or urine pregnancy test result at time of pre-treatment screening.
  11. Patients with reproductive potential must agree to use at least one form of barrier contraception prior to study entry and for up to 30 days beyond the last administration of study drug.
  12. Patients must be capable of providing informed consent and must be willing to provide written informed consent prior to the start of any study-specific procedures.

Exclusion Criteria:

  1. Patients may not have had prior chemotherapy, radiotherapy, hormonal therapy, or biologic therapy in the 4 weeks prior to study entry with the exception of mitomycin C or nitrosoureas, for which patients must be 6 weeks from prior treatment. For patients who have been treated with targeted therapy, 5 half-lives of that therapy (or 28 days, whichever is shorter) must have passed prior to enrollment in the study.
  2. Part 2 only: Patients may not have had prior treatment with docetaxel.
  3. Part 2 only: Patients with plasma total bilirubin > ULN; ALT and/or AST > 1.5 X ULN concomitant with alkaline phosphatase > 2.5 X ULN.
  4. Patients may not have any concomitant condition that could compromise the objectives of this study and the patients' compliance and ability to tolerate this therapy and complete at least 2 cycles of therapy, including, but not limited to the following:

    • Congestive heart failure or uncontrolled angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension, or dysrhythmias.
    • Active infection.
    • Unstable diabetes mellitus.
    • Psychiatric disorder that may interfere with consent and/or protocol compliance.
    • Uncontrolled seizure activity.
    • Prior history of inflammatory bowel disease.
    • Prior history of pulmonary fibrosis.
    • Prior history of cardiomyopathy.
  5. Patients with a history of central nervous system (CNS) malignancy.
  6. Pregnant or breastfeeding women.
  7. Patients with another malignancy in the past 3 years except: curatively treated non-melanoma skin cancer, or carcinoma in situ (either cervix or breast) that does not require further treatment.
  8. Patients with known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection.
  9. Part 2 only: Patients with a history of severe hypersensitivity reaction to drugs formulated with polysorbate 80 (for example, drugs formulated with polysorbate 80 include, but are not limited to: Aranesp, Eprex, Cordarone, some vaccines).
  10. Part 2 only: Patients with >= grade 2 peripheral neuropathy.
  11. Patients with an underlying diagnosis or disease state associated with an increased risk of bleeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01837667

United States, California
City of Hope National Medical Center
Duarte, California, United States, 91010
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Nevada
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States, 89169
United States, Texas
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States, 75246
Texas Oncology - Tyler
Tyler, Texas, United States, 75702
Sponsors and Collaborators
Lixte Biotechnology Holdings, Inc.
Principal Investigator: Vincent Chung, MD, FACP City of Hope National Medical Center
Principal Investigator: Aaron Mansfield, MD Mayo Clinic
Principal Investigator: Fadi Braiteh, MD Comprehensive Cancer Centers of Nevada
Principal Investigator: Carlos Becerra, MD Texas Oncology - Baylor Charles A Sammons Cancer Center
Principal Investigator: Donald Richards, MD Texas Oncology - Tyler
  More Information

Study Data/Documents: publication  This link exits the site
"Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors" has been published by Clinical Cancer Research

Responsible Party: Lixte Biotechnology Holdings, Inc. Identifier: NCT01837667     History of Changes
Other Study ID Numbers: L12-20661
Study First Received: April 18, 2013
Last Updated: January 23, 2017

Additional relevant MeSH terms:
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on April 26, 2017